Denna sida på svenska

Eva Hellström Lindberg

Professor/senior physician

Visiting address : M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Stockholm, Sweden
Postal address : Department of Medicine, Huddinge (MedH), H7, Unit for Hematology, M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Stockholm, Sweden
Delivery address : M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Srockholm, Sweden

About me

I am double specialist in hematology and internal medicine since 1993, and professor of hematology at the Department of Medicine, Huddinge since 2009. I have worked within the translational research field for many years and been actively involved in strategic research questions. I have been president both for European Association of Hematology and for Swedish Society of Hematology.

Education

I was previously involved in graduate training within ethics and communication skills, but is presently more focused on creating a good environment for post graduate student. I was chair for doctoral studies at the department for medicine for five years.

Research description

My research program focuses on the hemopoietic stem cell malignancy myelodysplastic syndromes (MDS) and include genetic, epigenetic, and cellular studies. The aim is to understand mechanisms for disease progression, leukemic transformation, and erythroid failure. I also lead a clinical specialist program for patients with this disease, as well as the Nordic MDS research group, which drives a broad clinical trial and biomarker program. I am also chair for the newly started Center for Hematology and Regenerative Medicine, Huddinge, a translational research environment combining basic and clinical competences within hematology, regenerative medicine and immunology.

Academic honours, awards and prizes

I have received both junior and senior research awards from the Swedish Cancer Society.

Publications

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, et al
Oncotarget 2017;8(17):28812-28825

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
Garelius Hk, Johnston Wt, Smith Ag, Park S, De Swart L, Fenaux P, et al
Journal of internal medicine 2017;281(3):284-299

Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data
Sandmann S, De Graaf Ao, Karimi M, Van Der Reijden Ba, Hellström-lindberg E, Jansen Jh, et al
Scientific reports 2017;7():43169-

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, et al
Haematologica 2017;102(3):498-508

Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice
Leroy B, Ballinger Ml, Baran-marszak F, Bond Gl, Braithwaite A, Concin N, et al
Cancer research 2017;77(6):1250-1260

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome
Botezatu L, Michel Lc, Makishima H, Schroeder T, Germing U, Haas R, et al
Experimental hematology 2016;44(7):590-595.e1

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Tobiasson M, Mclornan Dp, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, et al
Oncotarget 2016;7(16):22103-15

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality
Dimitriou M, Woll Ps, Mortera-blanco T, Karimi M, Wedge Dc, Doolittle H, et al
Oncotarget 2016;7(45):72685-72698

The European Hematology Association Roadmap for European Hematology Research: a consensus document
Eha Roadmap European Hematology Re, Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, et al
HAEMATOLOGICA 2016;101(2):115-208

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
Conte S, Katayama S, Vesterlund L, Karimi M, Dimitriou M, Jansson M, et al
British journal of haematology 2015;171(4):478-90

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta Mg, Jädersten M, et al
Nature communications 2015;6():5901-

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia
Karimi M, Nilsson C, Dimitriou M, Jansson M, Matsson H, Unneberg P, et al
Haematologica 2015;100(6):e223-5

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
Sohlberg E, Pfefferle A, Andersson S, Baumann Bc, Hellström-lindberg E, Malmberg Kj
Oncotarget 2015;6(33):34178-90

Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes
Ryblom H, Hast R, Hellström-lindberg E, Winterling J, Johansson E
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2015;19(2):99-106

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M, et al
BLOOD 2015;126(2):233-41

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies
Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, et al
ANNALS OF HEMATOLOGY 2015;94(1):23-34

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
De Swart L, Smith A, Johnston Tw, Haase D, Droste J, Fenaux P, et al
British journal of haematology 2015;170(3):372-83

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome
Ueda Y, Calado Rt, Norberg A, Kajigaya S, Roos G, Hellstrom-lindberg E, et al
BMC MEDICAL GENETICS 2014;:68-

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine
Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen Se, et al
European journal of haematology 2014;93(5):439-45

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation
Grövdal M, Karimi M, Tobiasson M, Reinius L, Jansson M, Ekwall K, et al
Leukemia 2014;28(2):411-3

Cardiac iron overload assessed by T2*magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients
Bowen Dt, Hellstrom-lindberg E, Steensma Dp
BRITISH JOURNAL OF HAEMATOLOGY 2014;164(4):610-1

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model
Fenaux P, Seymour Jf, Santini V, Silverman L, Gore S, List A, et al
Leukemia research 2014;38(2):258-62

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
Tobiasson M, Dybedahl I, Holm Ms, Karimi M, Brandefors L, Garelius H, et al
Blood cancer journal 2014;4():e189-

Lung transplantation in telomerase mutation carriers with pulmonary fibrosis
Silhan Ll, Shah Pd, Chambers Dc, Snyder Ld, Riise Gc, Wagner Cl, et al
The European respiratory journal 2014;44(1):178-87

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Woll Ps, Kjällquist U, Chowdhury O, Doolittle H, Wedge Dc, Thongjuea S, et al
Cancer cell 2014;25(6):794-808

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
Giagounidis A, Mufti Gj, Mittelman M, Sanz G, Platzbecker U, Muus P, et al
EUROPEAN JOURNAL OF HAEMATOLOGY 2014;93(5):429-38

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti Gj, Kulasekararaj A, et al
Haematologica 2014;99(6):1041-9

Survey of professional competence in hematology in Europe
Lindberg Eh, Almeida A, Enoksson F, De Wit Td, Strivens J, Naeve A, et al
HAEMATOLOGICA 2014;99(3):404-8

A European strategy for targeted education in hematology
Strivens J, Hellstrom-lindberg E, Bjerrum Ow, Toh Ch
HAEMATOLOGICA 2013;98(7):1000-2

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Gore Sd, Fenaux P, Santini V, Bennett Jm, Silverman Lr, Seymour Jf, et al
HAEMATOLOGICA 2013;98(7):1067-72

Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
Saft L, Björklund E, Berg E, Hellström-lindberg E, Porwit A
Leukemia research 2013;37(3):266-73

Clinical and biological implications of driver mutations in myelodysplastic syndromes
Int Canc Genome Consortium, Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, et al
BLOOD 2013;122(22):3616-27

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions
Aziz A, Baxter Ej, Edwards C, Cheong Cy, Ito M, Bench A, et al
JOURNAL OF CLINICAL INVESTIGATION 2013;123(5):2169-82

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Malcovati L, Hellstrom-lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al
BLOOD 2013;122(17):2943-64

Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q
Treppendahl Mb, Mollgard L, Hellstrom-lindberg E, Cloos P, Gronbaek K
EUROPEAN JOURNAL OF HAEMATOLOGY 2013;90(3):259-60

Erythropoiesis stimulating agents and other growth factors in low-risk MDS
Hellström-lindberg E, Van De Loosdrecht A
Best practice & research. Clinical haematology 2013;26(4):401-10

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes
Pellagatti A, Benner A, Mills Ki, Cazzola M, Giagounidis A, Perry J, et al
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(28):3557-64

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
Van De Loosdrecht Aa, Ireland R, Kern W, Della Porta Mg, Alhan C, Balleisen Js, et al
LEUKEMIA & LYMPHOMA 2013;54(3):472-5

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Koreth J, Pidala J, Perez Ws, Deeg Hj, Garcia-manero G, Malcovati L, et al
JOURNAL OF CLINICAL ONCOLOGY 2013;31(21):2662-70

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts
Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-blanco T, et al
Leukemia 2013;27(4):889-896

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome inAML
Treppendahl Mb, Qiu Xn, Sogaard A, Yang Xj, Nandrup-bus C, Hother C, et al
BLOOD 2012;119(1):206-16

H-Net, the European Network for Harmonization of Training in Hematology, and its policy
De Wit Td, Hellstrom-lindberg E, Jager U, Evans-jones G, Smand C
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2012;97(12):1776-8

Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome
Fleming S, Hellstrom-lindberg E, Burbury K, Seymour Jf
LEUKEMIA & LYMPHOMA 2012;53(8):1613-6

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
Gohring G, Lange K, Hofmann W, Nielsen Kv, Hellstrom-lindberg E, Roy L, et al
LEUKEMIA 2012;26(2):356-8

Towards a joint definition of European hematology
Curriculum Update Working Grp, Ossenkoppele G, Evans-jones G, Jaeger U, Hellstrom-lindberg E
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2012;97(5):636-7

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Mds-004 Lenalidomide Del5q Study, Fenaux P, Giagounidis A, Selleslag D, Beyne-rauzy O, Mufti G, et al
BLOOD 2011;118(14):3765-76

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Mollgard L, Saft L, Treppendahl Mb, Dybedal I, Norgaard Jm, Astermark J, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2011;96(7):963-71

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Int Canc Genome Consortium, Assoc Italiana Ricerca Canc Grp, Malcovati L, Papaemmanuil E, Bowen Dt, Boultwood J, et al
BLOOD 2011;118(24):6239-46

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Silverman Lr, Fenaux P, Mufti Gj, Santini V, Hellstrom-lindberg E, Gattermann N, et al
CANCER 2011;117(12):2697-702

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
Gohring G, Giagounidis A, Busche G, Hofmann W, Kreipe Hh, Fenaux P, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2011;96(2):319-22

Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT
Tobiasson M, Olsson R, Hellstrom-lindberg E, Mattsson J
BONE MARROW TRANSPLANTATION 2011;46(5):719-26

Is there a graft-versus-MDS effect after haematopoietic allogeneic stem cell transplantation?
Remberger M, Mattsson J, Hassan Z, Hagglund H, Le Blanc K, Machaczka M, et al
BONE MARROW TRANSPLANTATION 2011;:S369-S369

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta Mg, et al
BRITISH JOURNAL OF HAEMATOLOGY 2011;155(2):272-4

Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
Nilsson-ehle H, Birgegard G, Samuelsson J, Antunovic P, Astermark J, Garelius H, et al
EUROPEAN JOURNAL OF HAEMATOLOGY 2011;87(3):244-52

Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Int Canc Genome Consortium, Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, et al
NEW ENGLAND JOURNAL OF MEDICINE 2011;365(15):1384-95

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G, et al
JOURNAL OF CLINICAL ONCOLOGY 2011;29(15):1971-9

ANALYSIS OF MICRO RNA EXPRESSION DURING ERYTHROID DIFFERENTIATION OF RARS MYELOID STEM CELLS IN COMPARISON WITH NORMAL BONE MARROW STEM CELLS
Arzenani Mk, Corcoran M, Nikpour M, Liu A, Jansson M, Forsblom L, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:378-378

ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AT DIAGNOSIS IN AN EUROPEAN REGISTRY FOR LOW RISK AND INTERMEDIATE-1 RISK MDS: REPORT ON THE FIRST 322 PATIENTS
Stauder R, Smith A, De Witte T, Droste J, Fenaux P, Symeonidis A, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:131-132

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux P, Mufti Gj, Hellstrom-lindberg E, Santini V, Gattermann N, Germing U, et al
JOURNAL OF CLINICAL ONCOLOGY 2010;28(4):562-9

CYTOGENETIC FOLLOW-UP IN PATIENTS WITH IN MYELODYSPLASTIC SYNDROME TREATED WITH LENALIDOMIDE: IMPACT OF KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDIZATION
Gohring G, Giagounidis A, Hofmann W, Buesche G, Kreipe H, Cazzola M, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:85-85

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta Mg, et al
LEUKEMIA 2010;24(4):756-64

DETECTION OF TP53 MUTATIONS IN LOW-RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) IS ASSOCIATED WITH DISEASE PROGRESSION
Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Hast R, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:126-126

EFFECT OF BASELINE EPO AND PRIOR ERYTHROPOIESIS STIMULATING AGENTS ON RBC TRANSFUSION INDEPENDENCE IN LOW-/INT-1-RISK MDS WITH DEL5Q TREATED WITH LENALIDOMIDE: A RANDOMIZED PHASE 3 STUDY (MDS-004)
Fenaux P, Giagounidis A, Selleslag D, Knight R, Fu T, Hellstrom-lindberg E
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:125-125

Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes
Seymour Jf, Fenaux P, Silverman Lr, Mufti Gj, Hellstrom-lindberg E, Santini V, et al
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2010;76(3):218-27

Erythropoiesis-stimulating agents in myelodysplastic syndromes
Hellstrom-lindberg E
LEUKEMIA & LYMPHOMA 2010;51(7):1155-6

Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias Response
Vardiman J, Thiele J, Arber Da, Brunning R, Borowitz Mj, Porwit A, et al
BLOOD 2010;115(3):749-750

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia
Boultwood J, Perry J, Pellagatti A, Fernandez-mercado M, Fernandez-santamaria C, Calasanz Mj, et al
LEUKEMIA 2010;24(5):1062-5

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF
Nikpour M, Pellagatti A, Liu Aq, Karimi M, Malcovati L, Gogvadze V, et al
BRITISH JOURNAL OF HAEMATOLOGY 2010;149(6):844-54

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia
Deneberg S, Grovdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, et al
LEUKEMIA 2010;24(5):932-41

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
Grovdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, et al
BRITISH JOURNAL OF HAEMATOLOGY 2010;150(3):293-302

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
Santini V, Fenaux P, Mufti Gj, Hellstrom-lindberg E, Silverman Lr, List A, et al
EUROPEAN JOURNAL OF HAEMATOLOGY 2010;85(2):130-8

MOLECULAR PATHOGENESIS OF REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS
Liu A, Nikpour M, Hogstrand K, Forsblom A, Jansson M, Karimi M, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:125-126

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
Gohring G, Giagounidis A, Busche G, Kreipe Hh, Zimmermann M, Hellstrom-lindberg E, et al
ANNALS OF HEMATOLOGY 2010;89(4):365-74

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Tehranchi R, Woll Ps, Anderson K, Buza-vidas N, Mizukami T, Mead Aj, et al
NEW ENGLAND JOURNAL OF MEDICINE 2010;363(11):1025-37

Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
Fenaux P, Bowen D, Gattermann N, Hellstrom-lindberg E, Hofmann Wk, Pfeilstocker M, et al
LEUKEMIA RESEARCH 2010;34(11):1410-6

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Fenaux P, Gattermann N, Seymour Jf, Hellstrom-lindberg E, Mufti Gj, Duehrsen U, et al
BRITISH JOURNAL OF HAEMATOLOGY 2010;149(2):244-9

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34(+) blasts in myelodysplastic syndrome
Carlsten M, Baumann Bc, Simonsson M, Jadersten M, Forsblom Am, Hammarstedt C, et al
LEUKEMIA 2010;24(9):1607-16

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Kantarjian H, Fenaux P, Sekeres Ma, Becker Ps, Boruchov A, Bowen D, et al
JOURNAL OF CLINICAL ONCOLOGY 2010;28(3):437-44

Significance of JAK2 and TET2 mutations in myelodysplastic syndromes
Hellstrom-lindberg E
BLOOD REVIEWS 2010;24(2):83-90

TELOMERE SHORTENING AND AML PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q TREATED WITH LENALIDOMIDE
Gohring G, Lange K, Hofmann W, Buesche G, Kreipe H, Hellstrom-lindberg E, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;:378-379

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
De Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2010;95(10):1754-61

AZACITIDINE (AZA) IMPROVES OVERALL SURVIVAL (OS) IN WHO ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS WITH LOW BONE MARROW BLAST COUNTS
Fenaux Pf, Silverman Lr, Mufti Gj, Hellstrom-lindberg E, Santini V, Gattermann N, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:430-431

Chimerism analysis as a predictor of relapse of myelodysplastic syndrome after allogeneic stem cell transplantation
Tobiasson M, Olsson R, Remberger M, Hellstrom-lindberg E, Mattsson J
BONE MARROW TRANSPLANTATION 2009;:S276-S277

Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Jadersten M, Saft L, Pellagatti A, Gohring G, Wainscoat Js, Boultwood J, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;94(12):1762-6

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta Mg, et al
BLOOD 2009;114(22):306-306

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Int Vidaza High-risk Mds Survival, Fenaux P, Mufti Gj, Hellstrom-lindberg E, Santini V, Finelli C, et al
LANCET ONCOLOGY 2009;10(3):223-32

European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes
Bowen D, Droste J, Smith A, Fenaux P, Symeonidis A, Sanz G, et al
LEUKEMIA RESEARCH 2009;:S66-S67

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients
De Witte Tm, Smith A, Droste J, Fenaux P, Symeonidis A, Hellstrom-lindberg E, et al
BLOOD 2009;114(22):1466-1467

Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
Jadersten M, Saft L, Garelius H, Hast R, Nilsson L, Samuelsson J, et al
LEUKEMIA RESEARCH 2009;:S39-S39

EXPRESSION OF P53 OR CYTOPLASMIC NUCLEOPHOSMINE ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION IN MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q)
Jadersten Ms, Saft L, Garelius H, Hast R, Nilsson L, Samuelsson J, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:102-102

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
Boultwood J, Perry J, Pellagatti A, Giagounidis A, Malcovati L, Della Porta Mg, et al
BLOOD 2009;114(22):174-174

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
Nikpour M, Pellagatti A, Liu A, Karimi M, Malcovati L, Forsblom Am, et al
LEUKEMIA RESEARCH 2009;:S55-S55

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen
Mufti Gj, Gore Sd, Santini V, Fenaux P, Silverman Lr, Hagemeijer A, et al
BLOOD 2009;114(22):697-698

Lenalidomide abrogates the clonal advantage of del(5q) MDS stem cells via alteration of niche interactions
Scharenberg C, Jadersten M, Palmquist J, Forsblom L, Jansson M, Hellstrom-lindberg E
LEUKEMIA RESEARCH 2009;:S48-S48

LENALIDOMIDE ABROGATES THE CLONAL ADVANTAGE OF DEL(5Q) MDS STEM CELLS VIA ALTERATION OF NICHE INTERACTIONS
Scharenberg C, Jadersten M, Palmquist J, Forsblom L, Jansson M, Hellstrom-lindberg E
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:98-98

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
Mollgard L, Nilsson L, Kjeldsen L, Dybedal I, Dufva Ih, Garelius H, et al
BLOOD 2009;114(22):52-52

Low-risk MDS; transfusion therapy, growth factors and the European view on lenalidomide
Hellstrom-lindberg E
LEUKEMIA RESEARCH 2009;:S26-S27

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes
Pellagatti A, Marafioti T, Paterson Jc, Malcovati L, Della Porta Mg, Jadersten M, et al
BRITISH JOURNAL OF HAEMATOLOGY 2009;146(1):86-90

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Malcovati L, Della Porta Mg, Pietra D, Boveri E, Pellagatti A, Galli A, et al
BLOOD 2009;114(17):3538-45

Myelodysplastic syndromes: biology and treatment
Jadersten M, Hellstrom-lindberg E
JOURNAL OF INTERNAL MEDICINE 2009;265(3):307-28

Myeloid leukaemia in systemic lupus erythematosus-a nested case-control study based on Swedish registers
Lofstrom B, Backlin C, Sundstrom C, Hellstrom-lindberg E, Ekbom A, Lundberg Ie
RHEUMATOLOGY 2009;48(10):1222-6

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
Nikpour M, Pellagatti A, Liu A, Karimi M, Malcovati L, Forsblom A, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:99-99

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.
Gohring G, Giagounidis A, Busche G, Kreipe H, Zimmermann M, Hellstrom-lindberg E, et al
BLOOD 2009;114(22):1469-1469

Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)
Santini V, Silverman L, Seymour J, Fenaux P, Mufti G, Hellstrom-lindberg E, et al
LEUKEMIA RESEARCH 2009;:S133-S133

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004)
Fenaux P, Giagounidis A, Selleslag D, Beyne-rauzy O, Mufti Gj, Mittelman M, et al
BLOOD 2009;114(22):390-390

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Vardiman Jw, Thiele J, Arber Da, Brunning Rd, Borowitz Mj, Porwit A, et al
BLOOD 2009;114(5):937-51

Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
Silverman L, Fenaux P, Santini V, Seymour J, Mufti G, Hellstrom-lindberg E, et al
LEUKEMIA RESEARCH 2009;:S133-S134

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)
Fenaux P, Mufti Gj, Hellstrom-lindberg E, Santini V, Gattermann N, Sanz G, et al
BLOOD 2008;112(11):1244-1244

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
Mufti Gj, Bennett Jm, Goasguen J, Bain Bj, Baumann I, Brunning R, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2008;93(11):1712-7

Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS
Deneberg S, Grovdall M, Jansson M, Gaidzik Vi, Corbacioglu A, Nahi H, et al
BLOOD 2008;112(11):1146-1147

EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
Fenaux P, Gattermann N, Seymour J, Hellstrom-lindberg E, Mufti Gj, Duehrsen U, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2008;:90-90

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (>= 75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial
Seymour Jf, Fenaux P, Silverman Lb, Mufti Gj, Hellstrom-lindberg E, Santini V, et al
BLOOD 2008;112(11):1241-1242

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Jadersten M, Malcovati L, Dybedal I, Della Porta Mg, Invernizzi R, Montgomery Sm, et al
JOURNAL OF CLINICAL ONCOLOGY 2008;26(21):3607-13

Erythropoietins should be used according to guidelines
Aapro Ms, Birgegard G, Bokemeyer C, Cornes P, Foubert J, Gascon P, et al
LANCET ONCOLOGY 2008;9(5):412-3

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta M, et al
BLOOD 2008;112(11):1246-1246

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
Pellagati A, Hellstrom-lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta M, et al
BLOOD 2008;112(11):1246-1246

Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal- and translation-related genes
Pellagatti A, Hellstrom-lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta Mg, et al
BRITISH JOURNAL OF HAEMATOLOGY 2008;142(1):57-64

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells
Khan R, Schmidt-mende J, Karim M, Gogvadze V, Hassan M, Ekstrom Tj, et al
EXPERIMENTAL HEMATOLOGY 2008;36(2):149-57

Long-Term Cytogenetic Follow-up of MDS Patients with 5q-Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML
Gohring G, Giagounidis A, Aul C, Busche G, Kreipe H, Hellstrom-lindberg E, et al
BLOOD 2008;112(11):581-581

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)
Santini V, Fenaux P, Mufti Gj, Hellstrom-lindberg E, Silverman Lb, List A, et al
BLOOD 2008;112(11):583-584

Patients experience of being blood transfusion-dependent
Ryblom H, Hast R, Hellstrom-lindberg E, Johansson E
BONE MARROW TRANSPLANTATION 2008;:S399-S399

Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes
Hellstrom-lindberg E, Malcovati L
SEMINARS IN HEMATOLOGY 2008;45(1):14-22

Supportive care, growth factors, and new therapies in myelodysplastic syndromes
Hellstrom-lindberg E, Malcovati L
BLOOD REVIEWS 2008;22(2):75-91

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
Silverman Lr, Fenaux P, Mufti Gj, Santini V, Hellstrom-lindberg E, Gattermann N, et al
BLOOD 2008;112(11):91-91

The role of JAK2 mutations in RARS and other MDS
Hellström-lindberg E, Cazzola M
Hematology. American Society of Hematology. Education Program 2008;():52-9

The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H, et al
PLOS ONE 2008;3(4):e1970-

Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application
Bowen Dt, Fenaux P, Hellstrom-lindberg E, De Witte T
JOURNAL OF CLINICAL ONCOLOGY 2008;26(7):1180-author

Cobalt release from glazed earthenware: Observations in a case of lead poisoning
Selden Ai, Norberg C, Karlson-stiber C, Hellstrom-lindberg E
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2007;23(1):129-31

Differential expression of genes related to JAK-STAT pathway activation or megakaryocyte differentiation/maturation in CD34+cells from patients with refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T)
Malcovati L, Pietra D, Della Porta Mg, Pellagatti A, Travaglino E, Boveri E, et al
BLOOD 2007;110(11):124A-124A

Expression profiling of CD34+cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes
Pellagatti A, Cazzola M, Giagounidis A, Malcovati L, Della Porta Mg, Jadersten M, et al
LEUKEMIA RESEARCH 2007;:S35-S35

Gene expression profiling of CD34(+) cells in patients with the 5q-syndrome
Boultwood J, Pellagatti A, Cattan H, Lawrie Ch, Giagounidis A, Malcovati L, et al
BRITISH JOURNAL OF HAEMATOLOGY 2007;139(4):578-89

Hypomethylation and apoptosis in 5-azacytidine treated myeloid cells
Khan R, Schmidt-mende J, Karimi M, Forsblom Am, Gogvadze V, Hassan M, et al
LEUKEMIA RESEARCH 2007;:S62-S63

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Pellagatti A, Jadersten M, Forsblom Am, Cattan H, Christensson B, Emanuelsson Ek, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007;104(27):11406-11

Maintenance treatment with azacytidine for patients with high risk Myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy
Grovdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, et al
BLOOD 2007;110(11):251A-251A

Managing myelodysplastic syndromes in the frail elderly
Hellstrom-lindberg E
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2007;:S16-S16

Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
Grovdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, et al
CLINICAL CANCER RESEARCH 2007;13(23):7107-12

The molecular signature of MDS stem cells supports a stem-cell origin of 5q - myelodysplastic syndromes
Nilsson L, Eden P, Olsson E, Mansson R, Astrand-grundstrom I, Strombeck B, et al
BLOOD 2007;110(8):3005-14

Treatment of myelodysplastic syndromes with erythropoietin and G-CSF
Hellstrom-lindberg E
LEUKEMIA RESEARCH 2007;:S17-S17

Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need
Jadersten M, Malcovati L, Dybedal I, Della Porta Mg, Invernizzi R, Montgomery Sm, et al
LEUKEMIA RESEARCH 2007;:S113-S114

Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes
Lundberg Lg, Hellstrom-lindberg E, Kanter-lewensohn L, Lerner R, Palmblad J
LEUKEMIA RESEARCH 2006;30(3):247-53

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
Broliden Pa, Dahl Im, Hast R, Johansson B, Juvonen E, Kjeldsen L, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2006;91(5):667-70

Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival
Swedish Adult Acute Leukemia Regis, Juliusson G, Billstrom R, Gruber A, Hellstrom-linderg E, Hoglund M, et al
LEUKEMIA 2006;20(1):42-7

Early mitochondrial alterations in ATRA-induced cell death
Schmidt-mende J, Gogvadze V, Hellstrom-lindberg E, Zhivotovsky B
CELL DEATH AND DIFFERENTIATION 2006;13(1):119-28

Lead poisoning from souvenir earthenware
Hellstrom-lindberg E, Bjorklund A, Karlson-stiber C, Harper P, Selden Ai
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH 2006;79(2):165-8

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
Pellagatti A, Jadersten M, Forsblom Am, Cattan H, Christensson B, Emanuelsson Ek, et al
BLOOD 2006;108(11):256A-257A

Pharmacodynamic study of 5-azacytidine in the P39 cell line
Khan R, Aggerholm A, Hokland P, Hassan M, Hellstrom-lindberg E
EXPERIMENTAL HEMATOLOGY 2006;34(1):35-43

Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need.
Jadersten M, Malcovati L, Dybedal I, Della Porta Mg, Invernizzi R, Montgomery Sm, et al
BLOOD 2006;108(11):158A-158A

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom Am, et al
BLOOD 2005;106(1):247-53

A distinct molecular signature of purified cancer stem cells: Evidence for a hematopoietic stem cell origin of the 5q-syndrome
Nilsson L, Eden P, Olsson E, Mansson R, Astrand-grundstrom I, Strombeck B, et al
BLOOD 2005;106(11):175B-175B

Antiapoptotic role of growth factors in the Myelodysplastic syndromes: Concordance between in vitro and in vivo observations
Tehranchi R, Fadeel B, Schmidt-mende J, Forsblom Am, Emanuelsson E, Jadersten M, et al
CLINICAL CANCER RESEARCH 2005;11(17):6291-9

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jadersten M, Montgomery Sm, Dybedal I, Porwit-macdonald A, Hellstrom-lindberg E
BLOOD 2005;106(3):803-11

Management of anemia associated with myelodysplastic syndrome
Hellstrom-lindberg E
SEMINARS IN HEMATOLOGY 2005;42(2):S10-3

Stem cell transplantation from identical twins in patients with myelodysplastic syndromes
European Blood Marrow Transplantio, Kroger N, Brand R, Van Biezen A, Bron D, Blaise D, et al
BONE MARROW TRANSPLANTATION 2005;35(1):37-43

Strategies for biology- and molecular-based treatment of myelodysplastic syndromes
Lindberg Eh
CURRENT DRUG TARGETS 2005;6(6):713-25

Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents
Hellström-lindberg E
Hematology. American Society of Hematology. Education Program 2005;():161-6

Erythropoiesis is highly stimulated in CD34(+) cells in low-risk myelodysplastic syndromes (MDS) with an improper mitochondrial function
Tehranchi R, Invernizzi R, Zhivotovsky B, Fadeel B, Forsblom Am, Travaglino E, et al
BLOOD 2004;104(11):138A-138A

Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors
Ljung T, Back R, Hellstrom-lindberg E
HAEMATOLOGICA 2004;89(12):1446-53

Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells
Carlsson G, Aprikyan Aag, Tehranchi R, Dale Dc, Porwit A, Hellstrom-lindberg E, et al
BLOOD 2004;103(9):3355-61

Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplaistic syndromes (NIDS).
Brechignac S, Hellstrom-lindberg E, Bowen Dt, Dewitte Tm, Cazzola M, Fenaux P
BLOOD 2004;104(11):263B-263B

The WHO classification of MDS does make a difference
Howe Rb, Porwit-macdonald A, Wanat R, Tehranchi R, Hellstrom-lindberg E
BLOOD 2004;103(9):3265-70

Approach to anemia associated with myelodysplastic syndromes
Hellström-lindberg E
Current hematology reports 2003;2(2):122-9

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: significant effects on quality of life
Scandinavian Mds Grp, Hellstrom-lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl Ims, et al
BRITISH JOURNAL OF HAEMATOLOGY 2003;120(6):1037-46

Comparative trial of aazacitidine versus conventional care in high risk MDS patients: Methodologic challenges in designing an international survival trial.
List Af, Byrd Jc, Fenaux P, Gore Sd, Hellstrom-lindberg E, Mufti Gj, et al
BLOOD 2003;102(11):333B-334B

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors
Tehranchi R, Fadeel B, Forsblom Am, Christensson B, Samuelsson J, Zhivotovsky B, et al
BLOOD 2003;101(3):1080-6

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease
Hast R, Hellstrom-lindberg E, Ohm L, Bjorkholm M, Celsing F, Dahl Jm, et al
LEUKEMIA 2003;17(9):1827-33

Secondary acute leukemia in Sweden 1997-2001: Strong prognostic influence only in patients less than 70 years.
Juliusson G, Billstrom R, Gruber A, Hellstrom-lindberg E, Hoglund M, Karlsson K, et al
BLOOD 2003;102(11):240B-240B

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor and erythropoetin: Response and impact on survival in a long-term follow-up of 129 patients.
Jadersten M, Montgomery Sm, Astermark J, Carlsson M, Dahl Im, Dybedahl I, et al
BLOOD 2003;102(11):184A-185A

Accelerated apoptosis and defective Bcl-2 expression in the bone marrow of severe congenital neutropenia patients of the original Kostmann kindred: Evidence for anti-apoptotic effects of recombinant granulocyte colony-stimulating factor.
Fadeel B, Carlsson G, Aprikyan Aag, Dale Dc, Porwit A, Hellstrom-lindberg E, et al
BLOOD 2002;100(11):304A-304A

ATG and cyklosporin A as combination therapy in myelodysplastic syndromes RA and RAEB.
Broliden Pa, Dahl Im, Hast R, Johansson B, Juvonen E, Sjoo M, et al
BLOOD 2002;100(11):98A-98A

Granulocyte colony-stimulating factor and erythropoietin reduce mitochondria-dependent apoptosis of erythroid progenitors in low-risk myelodysplastic syndromes.
Tehranchi R, Fadeel B, Forsblom Am, Christensson B, Samuelsson J, Howe Rb, et al
BLOOD 2002;100(11):165A-166A

Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8
Nilsson L, Astrand-grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D, et al
BLOOD 2002;100(1):259-67

Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001
Hellström-lindberg E
International journal of hematology 2002;75(2):209-12

The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo
Hassan Z, Hellstrom-lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M
BONE MARROW TRANSPLANTATION 2002;30(3):141-7

The WHO classification of myelodysplastic syndromes (MDS) does make a difference.
Howe Rb, Porwit A, Wanat R, Tehranchi R, Hellstrom-lindberg E
BLOOD 2002;100(11):790A-791A

Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases
Lindberg Eh, Schmidt-mende J, Forsblom Am, Christensson B, Fadeel B, Zhivotovsky B
BRITISH JOURNAL OF HAEMATOLOGY 2001;112(3):714-26

Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?
Bowen Dt, Hellstrom-lindberg E
LEUKEMIA RESEARCH 2001;25(1):19-21

Classifying chronic myelomonocytic leukemia - In Reply
Greenberg P, Anderson J, Estey E, Fenaux P, Hamblin T, Hellstrom-lindberg E, et al
JOURNAL OF CLINICAL ONCOLOGY 2001;19(17):3791-3792

Evidence for a role of mitochondrial signaling in apoptosis in low-risk myelodysplastic syndromes (RA and RARS).
Tehranchi R, Fadeel B, Forsblom Am, Christensson B, Zhivotovsky B, Hellstrom-lindberg E
BLOOD 2001;98(11):730A-730A

Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts
Schmidt-mende J, Tehranchi R, Forsblom Am, Joseph B, Christensson B, Fadeel B, et al
LEUKEMIA 2001;15(5):742-51

High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD
Lindahl J, Kimby E, Bjorkstrand B, Christensson B, Hellstrom-lindberg E
LEUKEMIA RESEARCH 2001;25(3):267-70

Involvement and intrinsic deficiencies of hematopoietic stem cells in MDS patients with trisomy 8.
Nilsson L, Astrand-grundstrom I, Anderson K, Arvidsson I, Hokland P, Kjeldsen L, et al
BLOOD 2001;98(11):354A-354A

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro
Hassan Z, Hassan M, Hellstrom-lindberg E
LEUKEMIA 2001;15(8):1240-7

A final decision model for treating the anemia of myelodysplastic syndromes (MDS) with epo plus G-CSF.
Scandanavian Mds Grp, Hellstrom-lindberg E, Ahlgren T, Dahl I, Dybedal I, Grimfors G, et al
BLOOD 2000;96(11):546A-+

Evidence for involvement at the hematopoietic stem cell level in myelodysplastic syndromes with different chromosomal aberrations.
Nilsson L, Astrand-grundstrom I, Arvidsson I, Hellstrom-lindberg E, Hast R, Jacobsen Sew
BLOOD 2000;96(11):356A-356A

Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells
Schmidt-mende J, Hellstrom-lindberg E, Joseph B, Zhivotovsky B
JOURNAL OF IMMUNOLOGICAL METHODS 2000;245(1-2):91-4

Granulocyte-CSF inhibits fas-triggered apoptosis and enhances erythroid colony growth in bone marrow cells from patients with sideroblastic anemia (RARS).
Schmidt-mende J, Tehranchi R, Forsblom Am, Christensson B, Joseph B, Fadeel B, et al
BLOOD 2000;96(11):834A-834A

Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level
Nilsson L, Astrand-grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-lindberg E, Hast R, et al
BLOOD 2000;96(6):2012-21

Problematic WHO reclassification of myelodysplastic syndromes
Int Mds Study Grp, Greenberg P, Anderson J, De Witte T, Estey E, Fenaux P, et al
JOURNAL OF CLINICAL ONCOLOGY 2000;18(19):3447-52

Randomized study comparing chemotherapy +/- GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
Leuk Grp Middle Sweden, Scand Mds Grp, Ohm Ac, Hast R, Bernell P, Celsing F, et al
BLOOD 2000;96(11):148A-148A

Busulfan-induced G2 arrest and apoptosis in P39 myeloid cell
Hassan Z, Hassan M, Hellstrom-lindberg E
BLOOD 1999;94(10):192B-192B

Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
Fadeel B, Hassan Z, Hellstrom-lindberg E, Henter Ji, Orrenius S, Zhivotovsky B
LEUKEMIA 1999;13(5):719-28

Erythroid apoptosis in ringsideroblastic anemia (RARS): Influence of fas antibodies, caspase inhibition and G-CSF.
Hellstrom-lindberg E, Schmidt-mende J, Backman-johansson C, Forsblom Am, Fadeel B, Zhivotovsky B
BLOOD 1999;94(10):105A-105A

Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation
Nordesjo-haglund G, Lonnqvist B, Lindberg G, Hellstrom-lindberg E
LANCET 1999;353(9155):846-

Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology
Scandinavian Mds Grp, Hellstrom-lindberg E, Kanter-lewensohn L, Nichol J, Ost A
BRITISH JOURNAL OF HAEMATOLOGY 1999;105(4):966-73

Treatment of adult myelodysplastic syndromes
Hellstrom-lindberg E
INTERNATIONAL JOURNAL OF HEMATOLOGY 1999;70(3):141-54

Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39
Hassan Z, Fadeel B, Zhivotovsky B, Hellstrom-lindberg E
EXPERIMENTAL HEMATOLOGY 1999;27(8):1322-9

A patient-oriented approach to treatment of myelodysplastic syndromes
Cazzola M, Anderson Je, Ganser A, Hellstrom-lindberg E
HAEMATOLOGICA 1998;83(10):910-35

Blocking effect of G-CSF and z-VAD-fmk on apoptosis induced with ATRA in P39 cell line.
Hassan Z, Forsblom A, Hellstrom-lindberg E
BLOOD 1998;92(10):419A-419A

Effects of fas and caspase interaction on apoptosis and proliferation in myelodysplastic bone marrow
Hellstrom-lindberg E, Forsblom Am, Syruckova Z, Christensen B, Fadeel B, Zhivotovsky B
BRITISH JOURNAL OF HAEMATOLOGY 1998;102(1):27-27

GM-CSP in combination, with chemotherapy does not improve the remission rate in acute leukemia after myelodysplastic syndromes a randomized study.
Leukemia Grp Middle Sweden Scandinavian Mds Grp, Bernell P, Hast R, Hellstrom-lindberg E, Celsing F, Linder O, et al
BLOOD 1998;92(10):615A-615A

P39/tsugane cell line as a model for apoptosis in MDS?
Hassan Z, Fadeel B, Zhivotovsky B, Forsblom Am, Hellstrom-lindberg E
BRITISH JOURNAL OF HAEMATOLOGY 1998;102(1):28-29

Spontaneous or cytokine-induced thrombocytopenia in myelodysplastic syndromes (MDS) is not related to increased serum thrombopoietin levels.
Hellstrom-lindberg E, Kanter-lewensohn L, Ost A, Nichol Jl
BLOOD 1998;92(10):421A-421A

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients
Hellstrom-lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl Im, et al
BLOOD 1998;92(1):68-75

Treatment of long-term anorexia and nausea after stem cell transplantation with low dose octreotide.
Nordesjo G, Ljungman P, Bjorkstrand B, Lindberg G, Hellstrom-lindberg E
BONE MARROW TRANSPLANTATION 1998;:S89-S89

Effects of G-CSF, EPO, SCF, ATRA and the CD 95 blocking antibody f(ab') 2 on in vitro apoptosis and proliferation in myelodysplastic (MDS) bone marrow.
Hellstromlindberg E, Forsblom Am, Syruckova Z, Christensen B
BLOOD 1997;90(10):2322-2322

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
Hellstromlindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, et al
BRITISH JOURNAL OF HAEMATOLOGY 1997;99(2):344-51

G-CSF influence on apoptosis induced by ATRA and VP-16 in P39 cell line.
Syruckova Z, Forsblom A, Hellstromlindberg E
BLOOD 1997;90(10):3486-3486

Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin
Hellstromlindberg E, Kanterlewensohn L, Ost A
LEUKEMIA RESEARCH 1997;21(5):415-25

Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: A comparison between FACS analysis and immunohistochemistry
Kanterlewensohn L, Hellstromlindberg E, Kock Y, Elmhornrosenborg A, Ost A
EUROPEAN JOURNAL OF HAEMATOLOGY 1996;56(3):124-9

Effects of all-trans retinoic acid (ATRA), granulocyte-CSF (G-CSF) and erythropoietin (EPO) on in vitro apoptosis and proliferation in myelodysplastic bone marrow.
Hellstromlindberg E, Forsblom Am
BLOOD 1996;88(10):371-371

Treatment of the anemia in MDS with G-CSF and EPO: Final report from a randomized phase II study.
Hellstromlindberg E, Tangen Jm, Grimfors G, Lindemalm C, Carlsson M, Oberg G, et al
BLOOD 1996;88(10):1805-1805

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies
Hellström-lindberg E
British journal of haematology 1995;89(1):67-71

Efficacy of G-CSF and EPO on the anaemia in patients with myelodysplastic syndromes (MDS).
Hellstromlindberg E, Negrin R, Stein R, Krantz S, Vardiman J, Ost A, et al
BLOOD 1995;86(10):1340-1340

Erythropoietic effectiveness and apoptosis in patients with myelodysplastic syndromes (MDS) treated with G-CSF and EPO.
Kanter L, Hellstromlindberg E, Kock Y, Rodensjo M, Ost A
BLOOD 1995;86(10):1339-1339

PERIPHERAL-BLOOD NEUTROPHIL MORPHOLOGY REFLECTS BONE-MARROW DYSPLASIA IN MYELODYSPLASTIC SYNDROMES
Widell S, Hellstromlindberg E, Kock Y, Lindberg M, Ost A, Hast R
AMERICAN JOURNAL OF HEMATOLOGY 1995;49(2):115-20

RECOMBINANT ERYTHROPOIETIN FOR MYELODYSPLASTIC SYNDROMES
Hellstromlindberg E
BRITISH JOURNAL OF HAEMATOLOGY 1995;91(1):257-258

Show all publications

Map